Simcere Pharmaceutical Group Past Earnings Performance
Past criteria checks 1/6
Simcere Pharmaceutical Group has been growing earnings at an average annual rate of 20.5%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 10.4% per year. Simcere Pharmaceutical Group's return on equity is 9.9%, and it has net margins of 10.8%.
Key information
20.5%
Earnings growth rate
17.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 10.4% |
| Return on equity | 9.9% |
| Net Margin | 10.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Simcere Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,608 | 715 | 2,855 | 1,563 |
| 30 Sep 23 | 6,806 | 1,928 | 2,997 | 1,708 |
| 30 Jun 23 | 6,999 | 3,144 | 3,138 | 1,853 |
| 31 Mar 23 | 6,659 | 2,038 | 2,985 | 1,790 |
| 31 Dec 22 | 6,324 | 931 | 2,835 | 1,728 |
| 30 Sep 22 | 5,952 | 972 | 2,709 | 1,585 |
| 30 Jun 22 | 5,579 | 1,013 | 2,584 | 1,441 |
| 31 Mar 22 | 5,290 | 1,260 | 2,501 | 1,429 |
| 31 Dec 21 | 5,000 | 1,507 | 2,419 | 1,417 |
| 30 Sep 21 | 4,852 | 1,274 | 2,306 | 1,366 |
| 30 Jun 21 | 4,703 | 1,042 | 2,193 | 1,315 |
| 31 Mar 21 | 4,606 | 856 | 2,088 | 1,228 |
| 31 Dec 20 | 4,509 | 670 | 1,982 | 1,142 |
| 30 Sep 20 | 4,528 | 699 | 1,990 | 1,030 |
| 30 Jun 20 | 4,548 | 728 | 1,997 | 918 |
| 31 Mar 20 | 4,792 | 866 | 2,183 | 817 |
| 31 Dec 19 | 5,037 | 1,004 | 2,368 | 716 |
| 31 Dec 18 | 4,514 | 734 | 2,512 | 447 |
| 31 Dec 17 | 3,868 | 350 | 2,433 | 212 |
| 30 Sep 13 | 2,027 | 193 | 1,328 | 200 |
| 30 Jun 13 | 2,111 | 42 | 1,413 | 217 |
Quality Earnings: S2P has a high level of non-cash earnings.
Growing Profit Margin: S2P's current net profit margins (10.8%) are lower than last year (14.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S2P's earnings have grown significantly by 20.5% per year over the past 5 years.
Accelerating Growth: S2P's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: S2P had negative earnings growth (-23.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.6%).
Return on Equity
High ROE: S2P's Return on Equity (9.9%) is considered low.